Fulcrum Therapeutics (FULC) Non-cash Items (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Non-cash Items data on file, last reported at $6.4 million in Q1 2026.

• Non-cash Items for Q1 2026 came in at $6.4 million, up 38.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.4 million (up 38.73% YoY), and the FY2025 annual result was $5.8 million, up 9.14% from the prior year.
• Non-cash Items declined to $6.4 million in Q1 2026 per FULC's latest filing, from $61.4 million in the prior quarter.
• Over five years, Non-cash Items peaked at $61.4 million in Q4 2025 and troughed at $664811.0 in Q2 2023.
• A 5-year average of $10.3 million and a median of $4.6 million in 2025 frame the typical range for Non-cash Items.
• The sharpest annual moves came in 2022 and 2024: Non-cash Items slumped 97.93% in 2022, then surged 1389.18% in 2024.
• A 5-year view of Non-cash Items shows it stood at $1.9 million in 2022, then jumped by 701.74% to $15.1 million in 2023, then tumbled by 64.58% to $5.4 million in 2024, then jumped by 1046.77% to $61.4 million in 2025, then slumped by 89.51% to $6.4 million in 2026.
• Business Quant data shows FULC's Non-cash Items at $6.4 million in Q1 2026, $61.4 million in Q4 2025, and $5.9 million in Q3 2025.